Name

AFYX Therapeutics

Legal name

AFYX Therapeutics A/S

Website

https://afyxtx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Specialty pharmaceuticals
• Drug reformulation services
• Radiosensitizer therapy
• Hypoxic cancer treatment
• Labor induction therapeutics

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: AFYX generates revenue through sales of reformulated and repurposed pharmaceutical products including Diaphine, Nimorazole, and Gefena. Revenue increased from DKK 8.9 million in Q4 2023 to DKK 12.9 million in Q4 2024, driven by higher Diaphine sales and Nimorazole growth, particularly in Norway.
2. Licensing and Distribution Partnerships: The company generates revenue through licensing agreements with distribution partners across various regions (Europe, Africa, Middle East) who commercialize AFYX products in their territories under exclusive or non-exclusive arrangements.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

AFYX Therapeutics is a clinical-stage and commercial specialty biopharmaceutical company that develops, reformulates, and commercializes established pharmaceutical compounds using its "Reversed Innovation" approach. The company sells reformulated drugs including Gefena (misoprostol 25µg oral tablet for induction of labour), Nimorazole/Nimox (hypoxic radiosensitizer for head and neck cancer), Diaphine (pain medication), and pipeline products based on its proprietary wet-surface Rivelin patch technology. Products are intended for hospital and specialist use and reach 46 global markets through regional distribution partners.

Product overview

AFYX Therapeutics is a Danish biopharmaceutical company focused on reformulation and repurposing of established pharmaceutical compounds. The company's product portfolio centers on its 'Reversed Innovation' strategy, which finds new indications for existing technologies. Core products include: Gefena (misoprostol 25 µg oral tablet) for labor induction in women's health; Nimorazole/Nimox as hypoxic radiosensitizers for head and neck cancer treatment; Diaphine for pain management; esketamine and clobetasol patch for cluster headaches and oral lichen planus respectively; and the proprietary Rivelin wet-surface patch technology for mucosal diseases. The company operates across 46 global markets through distribution partnerships, with products primarily intended for hospital and specialist use in oncology, women's health, pain, and rare diseases.

Differentiator

Problem solved

Functional benefit

Brands

• Gefena: Misoprostol 25 µg oral tablet for labor induction. Developed for pregnant women beyond their scheduled delivery date. Lower risk of complications compared to competing products. EU approved in May 2026.
• Nimorazole
• Diaphine
• Rivelin patch
• Esketamine
• Nimox

Products and services

• Gefena A ready-to-use 25 microgram oral misoprostol tablet for induction of labour in pregnant women beyond their scheduled delivery date, delivering the WHO-recommended low-dose formulation in a standardized tablet that eliminates risks of inaccurate dosing from manual preparation and shows lower risk of complications such as cesarean section and low Apgar scores compared to competing products.
• Nimorazole (also branded Nimox in certain markets) An innovative patented proprietary hypoxic radiosensitizer and DNA repair inhibitor used as adjunct to radiotherapy for head and neck cancer patients, demonstrated to reduce 3-year locoregional failure rate by nearly 40% (from 33.8% to 20.7%) versus control in clinical studies with over 10 years of real-world use in Denmark and Norway.
• Diaphine Pain medication that drove the largest contribution to AFYX's Q4 2024 revenue growth, with sales uplift concentrated in Norway.
• Rivelin Patch (Clobetasol patch) Proprietary patented patch technology that adheres to wet surfaces, being developed as a clobetasol topical corticosteroid patch for treatment of oral lichen planus and other mucosal diseases.
• Esketamine (cluster headache therapy) Therapy being developed for chronic and intermittent cluster headache, leveraging AFYX's pharmaceutical repurposing expertise to address an unmet medical need in neurological pain conditions.

Quantifiable outcome

• Nimorazole reduces 3-year risk of relapse by nearly 40% (from 33.8% to 20.7% control group) in head and neck cancer patients receiving radiotherapy
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• Adcock Ingram Critical CarecoreChannel Partner/ Reseller/ Distributor · 22 January 2026Strategic distribution partnership for exclusive distribution of Gefena (misoprostol 25µg oral tablet) for labor induction and Nimorazole for head and neck cancer in South Africa and 10 additional Sub-Saharan African countries. Adcock Ingram Critical Care brings strong local expertise and a well-established distribution network.
• LunatuscoreChannel Partner/ Reseller/ Distributor · 23 April 2025Distribution and sales collaboration for Gefena (misoprostol 25µg tablet) for induction of labor. Lunatus will distribute, commercialize and supply Gefena in United Arab Emirates, Qatar, Kuwait, Oman, Kingdom of Saudi Arabia, Bahrain, Iraq, and Jordan. Expected EU regulatory approval for Gefena in Q4 2025.
• Cevidra SAScoreChannel Partner/ Reseller/ Distributor · 13 January 2025Strategic partnership with Cevidra as local pharmaceutical Exploitant and distribution partner in France for head and neck cancer treatments. Cevidra offers fully integrated solutions including price and reimbursement, local pharmacovigilance, CRO services, distribution, and tailored promotional activities. Supports Early Access Programs (AAC, AAP) and Licensed Products (MA).
• Er-KimcoreChannel Partner/ Reseller/ Distributor · 6 January 2025Mutual sales and distribution collaboration for Gefena (induction of labor) and Nimox (hypoxic radiosensitizer for head and neck cancer) across 22 Central and Eastern European countries: Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Moldova, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia, Turkey, and Ukraine. Er-Kim has trusted by over 60 global pharmaceutical companies over 40 years.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Y-mAbs Therapeutics: Pediatric oncology biotech co-founded by the same CEO (Dr. Møller-San Pedro). Both pursue niche biopharmaceutical strategies with limited direct sales infrastructure and target underserved specialty oncology indications.
• Photocure ASA: Norwegian specialty pharma focused on Hexvix/Cysview for bladder cancer detection. Comparable in being a small Nordic specialty pharma commercializing niche oncology/hospital products through partner networks.
• Calliditas Therapeutics: Swedish specialty pharma that developed Nefecon (Tarpeyo) for IgA nephropathy. Comparable small-cap Nordic specialty pharma commercializing through partners in selected geographies with a focus on orphan/specialty indications.
• Camurus AB: Swedish specialty pharma with proprietary drug-delivery technology (FluidCrystal). Comparable as a small Nordic pharma leveraging a proprietary delivery/technology platform to reformulate established compounds into differentiated products.
• HRA Pharma (Perrigo): European specialty pharma with strong focus on women's health (including reproductive health and obstetrics). Comparable in addressing women's health indications through differentiated reformulations and partner-led commercialization in Europe.
• Shield Therapeutics: UK-listed specialty pharma commercializing Feraccru/Accrufer for iron deficiency through distribution partners across Europe and the US. Comparable asset-light commercial model targeting specialty/hospital channels.

Broad incumbents

• Genmab A/S: Large Danish biopharma co-founded by Dr. Møller-San Pedro. Not a direct competitor but represents the broader Danish biotech ecosystem and is the same management team's prior success, providing institutional context.

Emerging players

• BioInvent International: Swedish clinical-stage biotech developing immuno-oncology antibodies. Comparable as a small Nordic clinical-stage biopharma with a niche therapeutic focus and lean headcount.
• Orphazyme A/S: Danish clinical-stage biopharma developing therapies for rare diseases. Comparable as a small Danish biopharma targeting rare/specialty indications through limited commercial resources.

Others

• Adcock Ingram Holdings: South African pharmaceutical company and direct distribution partner for AFYX in Sub-Saharan Africa. Listed because of its commercial relationship and role as AFYX's route to the African market rather than as a competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AFYX_Tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AFYX Therapeutics